Company: DARE
Filing Date: 2025-02-14
Form Type: 8-K
Source: 0001493152-25-006958
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-02-14
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item      Notice                                                                            

As
previously reported, on August 12, 2024, Daré Bioscience, Inc. (the “ Company”) received a letter from The Nasdaq Stock
Market LLC (“ Nasdaq”) notifying the Company that it does not meet the requirement in Nasdaq Listing Rule 5550(b)(2) for continued
listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires a company listed on Nasdaq to maintain a minimum market
value of listed securities of $35.0 million (the “ Minimum MVLS Rule”). The Company was provided an initial period of 180
calendar days, or until February 10, 2025, to regain compliance with the Minimum MVLS Rule.

On
February 13, 2025, Nasdaq’s Listing Qualifications Department (the “ Staff”) notified the Company that because the Company
did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s common stock is subject to delisting
from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “ Panel”).

The
Company will timely request a hearing before the Panel, which request will stay the delisting of the Company’s common stock pending
the Panel’s decision following the hearing and the expiration of any extension period that the Panel may grant. Pursuant to published
Nasdaq guidance, hearings are typically scheduled 30 to 45 days following the hearing request, with the Panel typically issuing decisions
within 30 days of the hearing.

There
can be no assurance that the Panel will grant the Company any extension period within which to regain compliance with the Minimum MVLS
Rule, or if any such extension period is granted, that the Company will regain compliance with the Minimum MVLS Rule within such extension
period, or that the Company will be successful in otherwise maintaining the listing of its common stock on The Nasdaq Capital Market.

This
report contains forward-looking statements, including, but not limited to, the timing of the hearing and the timing of the decision of
the Panel. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied
by such forward-looking statements. In particular, the hearing may be scheduled, and the Panel may issue a decision, more quickly than
expected based on the typical time periods in published Nasdaq guidance, which shorter timeline(s) may be unfavorable for the Company
and the